Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition
November 01, 2024 15:05 ET
|
Teva Pharmaceutical Industries Ltd
IMPACT-TD Registry, the largest study evaluating holistic effects of tardive dyskinesia (TD), highlights that there is a high burden of TD on quality of life regardless of a person’s underlying mental...
Harness Therapeutics Appoints Experienced R&D Executive and Physician-Scientist, Dr Paulo Fontoura, as Non-Executive Director
September 04, 2024 03:00 ET
|
Harness Therapeutics
Dr Paulo Fontoura brings 20 years’ experience of working in the pharma industry, with the most recent 16 years focusing on translational medicine and clinical development approaches for one of the...
uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease
July 09, 2024 07:05 ET
|
uniQure Inc.
~ Achieved statistically significant, dose-dependent, and durable evidence of potential therapeutic benefit; Patients receiving high-dose AMT-130 showed 80% slowing of disease progression in the...
uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease
June 03, 2024 07:05 ET
|
uniQure Inc.
~ Designation based on 24-month interim Phase I/II clinical data for AMT-130 announced in December 2023 ~ ~ AMT-130 is the first therapeutic candidate to receive RMAT Designation for Huntington’s...
Harness Therapeutics appoints Leading World Experts in Neurodegenerative Diseases to its Scientific Advisory Board (SAB)
May 30, 2024 07:00 ET
|
Harness Therapeutics
Newly established SAB of prominent geneticists, biologists and Huntington’s disease specialists’ marks pivotal step in accelerating progress of lead programme HRN001 Cambridge, UK, May 30, 2024:...
uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
December 19, 2023 07:05 ET
|
uniQure Inc.
~ Patients treated with AMT-130 continue to show evidence of preserved neurological function with potential dose-dependent clinical benefits relative to an inclusion criteria-matched natural...
Huntington's Disease Market to Witness Upsurge in Growth by 2032, Predicts DelveInsight | Key Companies to Watch Out - Prilenia, Neurocrine, Annexon, SOM, Vaccinex, Sage, UniQure, Wave life sciences, Takeda, Medesis
November 01, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Huntington's Disease Market to Witness Upsurge in Growth by 2032, Predicts DelveInsight | Key Companies to Watch Out - Prilenia, Neurocrine, Annexon,...
Digital Brain Health Market Predicted to Reach US$ 382.9 billion by 2031, Growing at a 7.3% CAGR Says, Transparency Market Research
October 26, 2023 04:33 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The digital brain health market was valued at US$ 184.7 billion in 2021. The market is...
Hereditary Disease Foundation Announces Recipients of Inaugural Transformative Research Award
October 04, 2023 14:38 ET
|
Hereditary Disease Foundation
New York, Oct. 04, 2023 (GLOBE NEWSWIRE) -- The Hereditary Disease Foundation has announced that the recipients of its first Transformative Research Awards are two teams - one led by Beverly...
Vaccinex Reports Groundbreaking Findings at Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and Cancer
September 26, 2023 08:00 ET
|
Vaccinex, Inc.
"Pepinemab, a SEMA4D blocking antibody, is a novel potential treatment for neurodegenerative disease” will be a podium presentation at the 16th edition of the Clinical Trials on Alzheimer’s Disease...